Upcoming event
18th European Multidisciplinary Congress on Urological Cancers
Back

Tag: metastatic castration-sensitive prostate cancer

Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for de novo metastatic castration-sensitive prostate cancer

Patient-reported outcomes in men with metastatic castration-sensitive prostate cancer and homologous recombination repair gene alterations receiving talazoparib + enzalutamide vs placebo + ENZA: Results from the phase 3 TALAPRO-3 study